Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes.

Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, Detmar M.

Mod Pathol. 2005 Sep;18(9):1232-42.

2.

Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Gallego E, Vicioso L, Alvarez M, Hierro I, Pérez-Villa L, Blanes A, Matilla A.

Virchows Arch. 2011 May;458(5):621-30. doi: 10.1007/s00428-011-1044-7. Epub 2011 Jan 29.

PMID:
21279519
3.

Tumor lymphangiogenesis and melanoma metastasis.

Rinderknecht M, Detmar M.

J Cell Physiol. 2008 Aug;216(2):347-54. doi: 10.1002/jcp.21494. Review.

PMID:
18481261
4.

Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.

Liu B, Ma J, Wang X, Su F, Li X, Yang S, Ma W, Zhang Y.

Anat Rec (Hoboken). 2008 Oct;291(10):1227-35. doi: 10.1002/ar.20736.

5.

Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.

Wobser M, Siedel C, Schrama D, Bröcker EB, Becker JC, Vetter-Kauczok CS.

Arch Dermatol Res. 2006 Feb;297(8):352-7. Epub 2006 Jan 3.

PMID:
16395613
6.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
7.

Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.

Špirić Z, Eri Ž, Erić M.

Int J Surg Pathol. 2015 Dec;23(8):629-37. doi: 10.1177/1066896915583694. Epub 2015 Apr 24.

PMID:
25911567
8.

Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity.

Cianfarani F, Mastroeni S, Odorisio T, Passarelli F, Cattani C, Mannooranparampil TJ, Fortes C, Failla CM.

J Cutan Pathol. 2012 Sep;39(9):826-34. doi: 10.1111/j.1600-0560.2012.01955.x. Epub 2012 Jul 16.

PMID:
22804631
9.

Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.

Petitt M, Allison A, Shimoni T, Uchida T, Raimer S, Kelly B.

J Am Acad Dermatol. 2009 Nov;61(5):819-28. doi: 10.1016/j.jaad.2009.04.026.

PMID:
19836642
10.

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.

Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL.

Mod Pathol. 2004 Jul;17(7):747-55.

11.

Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva.

Heindl LM, Hofmann-Rummelt C, Adler W, Bosch JJ, Holbach LM, Naumann GO, Kruse FE, Cursiefen C.

Ophthalmology. 2011 Dec;118(12):2351-60. doi: 10.1016/j.ophtha.2011.05.025. Epub 2011 Aug 11.

PMID:
21835473
12.

Insights into the mechanisms of lymph node metastasis.

Nathanson SD.

Cancer. 2003 Jul 15;98(2):413-23. Review.

13.

Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.

Tobler NE, Detmar M.

J Leukoc Biol. 2006 Oct;80(4):691-6. Epub 2006 Jun 22. Review.

PMID:
16793912
14.

Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma.

Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR 3rd, Leong SP.

Arch Dermatol. 1998 Aug;134(8):983-7.

PMID:
9722728
15.

Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.

Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R.

Melanoma Res. 2007 Dec;17(6):393-9.

PMID:
17992123
16.

From tumor lymphangiogenesis to lymphvascular niche.

Hirakawa S.

Cancer Sci. 2009 Jun;100(6):983-9. doi: 10.1111/j.1349-7006.2009.01142.x. Epub 2009 Feb 20. Review.

17.

Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M.

Am J Pathol. 2003 Jun;162(6):1951-60.

18.

The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.

Sahni D, Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones R.

J Clin Pathol. 2005 Jul;58(7):715-21.

19.

Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Thompson JF, Scolyer RA.

Ann Surg. 2012 Jan;255(1):128-33. doi: 10.1097/SLA.0b013e3182306c72.

PMID:
21975320
20.

Sentinel node identification by scintigraphic methods in cutaneous melanoma.

Dias Moreira R, Altino de Almeida S, Maliska Guimarães CM, Resende JF, Gutfilen B, Barbosa da Fonseca LM.

J Exp Clin Cancer Res. 2005 Jun;24(2):181-5.

PMID:
16110749

Supplemental Content

Support Center